ARTBIO redefines cancer care by discovering and developing a new class of Alpha Radioligand Therapies (ARTs) powered by unique Pb-212 isotope technology. It is a global biotech with locations in Boston, Basel, London, and Oslo, offering a collaborative, supportive culture and competitive compensation.
You will develop clinical imaging and dosimetry strategies to support clinical development plans for ARTBIO's RLT agents.
You will design and implement imaging protocols, procedures, and standards for clinical studies, including quantitative imaging and dosimetry oversight.
You will provide oversight for site imaging, vendor management, and regulatory interactions, contributing to IND/CTA submissions and scientific presentations.